Shionogi inks $425M deal in pain drug alliance with Egalet

The Danish biotech Egalet has pocketed a $10 million upfront payment from Shionogi to collaborate on the development of abuse-resistant hydrocodone opioid pain drugs. Shionogi is also snapping up $15 million in equity and promising to pay up to $400 million-plus in development and sales milestones for any drugs that are eventually approved. Egalet, which has a U.S. office in Pennsylvania, recently filed for an IPO. "We believe this collaboration provides validation for our proprietary abuse-deterrent drug delivery platform and positions us to capitalize on our technology, both through the products to be developed under the collaboration and by enabling us to develop additional opioid candidates utilizing our platform technology," says CEO Bob Radie. Release

Suggested Articles

Yale scientists have combined the gene-editing system CRISPR with gene therapy to help the immune system find tough-to-spot tumor cells.

The planned deal hit a wall when a special committee set up by Eidos turned down BridgeBio’s third and final offer.

Shares in ReNeuron fell more than one-third after the release of top-line data at the start of the month but the biotech argued the data are positive.